Cormorant Asset Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Cormorant Asset Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-816,448	Closed	-$3.4M	–	84
2019 Q3	$3.4M	Sell	816,448 -89,781	-10%	-$716K	0.21%	62
2019 Q2	$11.9M	Buy	906,229 +66,587	+8%	+$816K	0.68%	43
2019 Q1	$7.99M	Sell	839,642 -258,284	-24%	-$1.02M	0.54%	45
2018 Q4	$3.39M	Buy	+1,097,926	New	+$4.35M	0.28%	59

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Cormorant Asset Management's PHAS Position: Q4 2019 in Review

Cormorant Asset Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2019, closing a stake of 816,448 shares — an estimated $3.4M sold.

Cormorant Asset Management first reported a position in PHAS in Q4 2018 and held it in 4 quarters. The position peaked at $11.9M in Q2 2019. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2019.

Cormorant Asset Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Cormorant Asset Management sold 816,448 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $3.4M.
Cormorant Asset Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
Cormorant Asset Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $11.9M in Q2 2019.
51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.